Opelousas General Health System announced that it has added a treatment site for monoclonal antibody therapy (mAb) at its South Campus.
The new site is in partnership with the Louisiana Department of Health, the hospital says.
This site will be open 5 days per week (Monday through Friday) from 8 a.m. to 8 p.m. The location, accoriding to OGHS, has the ability to serve approximately 50 patients daily.
For mAb therapy, patients must have a referral by their physician, community clinic or urgernt care clinic. Only medical providers can schedule appointments. This can be done by calling LDH’s clinical hotline at (337) 678-4700.
“We have been offering monoclonal antibody infusion since it became available but have only been able to do so in a limited capacity, due to staffing constraints and the need to shift staff to care for inpatients. We have seen significant improvement in COVID positive patients who meet the criteria and receive the infusion, in many cases reducing the severity of symptoms and reducing the need for being hospitalized. Through the collaboration with the Louisiana Department of Health, we were able to secure much needed physician, nursing, and administrative staffing to better meet the needs of our community,” said Tim Marks, Chief Population Health & Clinical Integration Officer at Opelousas General.
Monoclonal antibodies are man-made antibodies produced in a laboratory that can mimic the human immune system response to infection. mAbs are designed to block viral attachment and entry into human cells, thus neutralizing the virus that causes COVID-19.
Monoclonal antibody treatments must be prescribed by a physician. The treatment is done by intravenous (IV) infusion. mAbs may only be administered in settings in which health care providers have immediate access to medications to treat severe infusion reactions, such as allergic reaction, and the ability to activate the emergency medical system, as necessary. The new infusion centers all meet this requirement, according to OGHS.
Monoclonal antibody treatments may be used for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are within 10 days of the start of their symptoms, at least 12 years of age or older and weigh at least 40 kilograms (88 pounds), and are at a high risk for progressing to severe COVID-19 and/or hospitalization.
Eligibility criteria
In order to be eligible for mAb treatment, the patient must meet all of the following:
- Have a positive test for SARS-CoV-2 (molecular/PCR or antigen)
- Are within 10 days of the start of their symptoms
- Are at least 12 years of age or older and weigh at least 40 kilograms (88 pounds)
- Are at a high risk for progressing to severe COVID-19 and/or hospitalization
For more information about mAbs, visit the LA Department of Health COVID-19 Information Site or the Opelousas General Health System COVID-19 Resources Site.
------------------------------------------------------------
Stay in touch with us anytime, anywhere.
To reach the newsroom or report a typo/correction, click HERE.
Sign up for newsletters emailed to your inbox. Select from these options: Breaking News, Evening News Headlines, Latest COVID-19 Headlines, Morning News Headlines, Special Offers
